Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation

The proteasome inhibitor bortezomib is the most successfully applied chemotherapeutic drug for treating multiple myeloma. However, its clinical efficacy reduced due to resistance development. The underlying molecular mechanisms of bortezomib resistance are poorly understood. In this study, by combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Hongyi, Gu, Yuanliang, Wang, Wenjuan, Wang, Xuyao, Ye, Xiaojuan, Xin, Chao, Lu, Mengjiao, Reddy, B. Ashok, Shu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972929/
https://www.ncbi.nlm.nih.gov/pubmed/31964975
http://dx.doi.org/10.1038/s41598-020-57698-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972929/
https://www.ncbi.nlm.nih.gov/pubmed/31964975
http://dx.doi.org/10.1038/s41598-020-57698-0

Ejemplares similares